Voxilaprevir: Difference between revisions
Content deleted Content added
+ cite |
Closing 2020 merge proposal; uncontested objection and no support; see Talk:Sofosbuvir/velpatasvir/voxilaprevir#Merge proposal |
||
Line 1: | Line 1: | ||
{{short description|Protease inhibitor}} |
{{short description|Protease inhibitor}} |
||
{{Merge to|Sofosbuvir/velpatasvir/voxilaprevir|date=September 2020}} |
|||
{{Use dmy dates|date=January 2020}} |
{{Use dmy dates|date=January 2020}} |
||
{{Infobox drug |
{{Infobox drug |
Revision as of 06:48, 27 July 2021
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
PDB ligand | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
Density | 1.4±0.1[1] g/cm3 |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]
On 18 July 2017, Vosevi was approved by Food and drug administration.[4]
References
- ^ "voxilaprevir_msds".
- ^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556.
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C